Melatonin and pancreatic cancer: Current knowledge and future perspectives

Tamtaji, O.R. and Mirhosseini, N. and Reiter, R.J. and Behnamfar, M. and Asemi, Z. (2019) Melatonin and pancreatic cancer: Current knowledge and future perspectives. Journal of Cellular Physiology, 234 (5). pp. 5372-5378.

Full text not available from this repository.
Official URL:


Pancreatic cancer has a high mortality rate due to the absence of early symptoms and subsequent late diagnosis; additionally, pancreatic cancer has a high resistance to radio- and chemotherapy. Multiple inflammatory pathways are involved in the pathophysiology of pancreatic cancer. Melatonin an indoleamine produced in the pineal gland mediated and receptor-independent action is the pancreas and other where has both receptors. Melatonin is a potent antioxidant and tissue protector against inflammation and oxidative stress. In vivo and in vitro studies have shown that melatonin supplementation is an appropriate therapeutic approach for pancreatic cancer. Melatonin may be an effective apoptosis inducer in cancer cells through regulation of a large number of molecular pathways including oxidative stress, heat shock proteins, and vascular endothelial growth factor. Limited clinical studies, however, have evaluated the role of melatonin in pancreatic cancer. This review summarizes what is known regarding the effects of melatonin on pancreatic cancer and the mechanisms involved. © 2018 Wiley Periodicals, Inc.

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: melatonin; melatonin receptor; protein Bax; protein bcl 2; vasculotropin, cancer cell; cancer chemotherapy; cancer survival; drug mechanism; endocrine pancreas; exocrine pancreas; human; mortality rate; oxidative stress; pancreas cancer; pineal body; priority journal; Review; tumor growth
Subjects: Nutrition
Biochemistry, Genetics and Molecular Biology
Divisions: Faculty of Medicine > Basic Sciences > Department of Biochemistry
Depositing User: ART . editor
Date Deposited: 29 May 2019 11:48
Last Modified: 29 May 2019 11:48

Actions (login required)

View Item View Item